Clinical Trial Update: Stroke Prevention With Hydroxyurea Enabled Through Research and Education (SPHERE) [Phase 2]

View source ↗

Summary

SPHERE is a Phase 2 trial evaluating hydroxyurea to prevent stroke in children with sickle cell disease. Enrollment is by invitation and the study is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• HYDROXYUREA (Hydroxyurea)

Snippet

Sponsor: Children's Hospital Medical Center, Cincinnati | Conditions: Sickle Cell Anemia in Children | Phase 2 | Status: ENROLLING_BY_INVITATION